1202 related articles for article (PubMed ID: 19528959)
1. Clostridium difficile infection: new developments in epidemiology and pathogenesis.
Rupnik M; Wilcox MH; Gerding DN
Nat Rev Microbiol; 2009 Jul; 7(7):526-36. PubMed ID: 19528959
[TBL] [Abstract][Full Text] [Related]
2. Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.
Nitzan O; Elias M; Chazan B; Raz R; Saliba W
World J Gastroenterol; 2013 Nov; 19(43):7577-85. PubMed ID: 24282348
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in Clostridium difficile-associated disease.
Monaghan T; Boswell T; Mahida YR
Gut; 2008 Jun; 57(6):850-60. PubMed ID: 18252748
[TBL] [Abstract][Full Text] [Related]
4. Clostridium difficile drug pipeline: challenges in discovery and development of new agents.
Jarrad AM; Karoli T; Blaskovich MA; Lyras D; Cooper MA
J Med Chem; 2015 Jul; 58(13):5164-85. PubMed ID: 25760275
[TBL] [Abstract][Full Text] [Related]
5. The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge.
Dubberke ER; Haslam DB; Lanzas C; Bobo LD; Burnham CA; Gröhn YT; Tarr PI
Zoonoses Public Health; 2011 Feb; 58(1):4-20. PubMed ID: 21223531
[TBL] [Abstract][Full Text] [Related]
6. Future novel therapeutic agents for Clostridium difficile infection.
Koo HL; Garey KW; Dupont HL
Expert Opin Investig Drugs; 2010 Jul; 19(7):825-36. PubMed ID: 20521993
[TBL] [Abstract][Full Text] [Related]
7. Growing consumption of antibiotics and epidemiology of Clostridioides difficile infections in Poland: A need to develop new solutions.
Jachowicz E; Pobiega M; Różańska A; Wójkowska-Mach J
Acta Microbiol Immunol Hung; 2020 Jun; 67(2):79-86. PubMed ID: 31813263
[TBL] [Abstract][Full Text] [Related]
8. In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy.
Carman RJ; Boone JH; Grover H; Wickham KN; Chen L
Antimicrob Agents Chemother; 2012 Nov; 56(11):6019-20. PubMed ID: 22908175
[TBL] [Abstract][Full Text] [Related]
9. Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.
Tsutsumi LS; Owusu YB; Hurdle JG; Sun D
Curr Top Med Chem; 2014; 14(1):152-75. PubMed ID: 24236721
[TBL] [Abstract][Full Text] [Related]
10. The Clostridium difficile PCR ribotype 027 lineage: a pathogen on the move.
Valiente E; Cairns MD; Wren BW
Clin Microbiol Infect; 2014 May; 20(5):396-404. PubMed ID: 24621128
[TBL] [Abstract][Full Text] [Related]
11. Clostridium difficile infection: molecular pathogenesis and novel therapeutics.
Rineh A; Kelso MJ; Vatansever F; Tegos GP; Hamblin MR
Expert Rev Anti Infect Ther; 2014 Jan; 12(1):131-50. PubMed ID: 24410618
[TBL] [Abstract][Full Text] [Related]
12. Relationship between antibiotic consumption and Clostridium difficile-associated diarrhea: an epidemiological note.
Kaier K; Frank U
Antimicrob Agents Chemother; 2009 Oct; 53(10):4574-5. PubMed ID: 19770290
[No Abstract] [Full Text] [Related]
13. Clostridium difficile infection: a comprehensive review.
Kachrimanidou M; Malisiovas N
Crit Rev Microbiol; 2011 Aug; 37(3):178-87. PubMed ID: 21609252
[TBL] [Abstract][Full Text] [Related]
14. Novel risk factors for recurrent Clostridium difficile infection in children.
Nicholson MR; Thomsen IP; Slaughter JC; Creech CB; Edwards KM
J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):18-22. PubMed ID: 25199038
[TBL] [Abstract][Full Text] [Related]
15. Clostridium difficile infection in the intensive care unit.
Riddle DJ; Dubberke ER
Infect Dis Clin North Am; 2009 Sep; 23(3):727-43. PubMed ID: 19665092
[TBL] [Abstract][Full Text] [Related]
16. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile.
Britton RA; Young VB
Gastroenterology; 2014 May; 146(6):1547-53. PubMed ID: 24503131
[TBL] [Abstract][Full Text] [Related]
17. The emergence of 'hypervirulence' in Clostridium difficile.
Cartman ST; Heap JT; Kuehne SA; Cockayne A; Minton NP
Int J Med Microbiol; 2010 Aug; 300(6):387-95. PubMed ID: 20547099
[TBL] [Abstract][Full Text] [Related]
18. Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains.
Theriot CM; Koumpouras CC; Carlson PE; Bergin II; Aronoff DM; Young VB
Gut Microbes; 2011; 2(6):326-34. PubMed ID: 22198617
[TBL] [Abstract][Full Text] [Related]
19. Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile.
Huang JS; Jiang ZD; Garey KW; Lasco T; Dupont HL
Antimicrob Agents Chemother; 2013 Jun; 57(6):2690-3. PubMed ID: 23545528
[TBL] [Abstract][Full Text] [Related]
20. The flagellin FliC of Clostridium difficile is responsible for pleiotropic gene regulation during in vivo infection.
Barketi-Klai A; Monot M; Hoys S; Lambert-Bordes S; Kuehne SA; Minton N; Collignon A; Dupuy B; Kansau I
PLoS One; 2014; 9(5):e96876. PubMed ID: 24841151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
